金沙app软件

My interest is in first-in-human, first-in-class and Phase 1 clinical trials of novel agents. As Director Physician in Early Phase Oncology, I lead the clinical development of a range of experimental therapies. I review clinical data from the Phase I/II trials and provide input on the strategic direction of the programme.

At AstraZeneca we have an exciting 文件夹 of pipeline drugs, particularly in the DNA Damage Response arena. This offers me a unique opportunity to contribute to scientifically driven combination trials and comparative studies to aid investment decisions.

My biggest motivation is giving patients the opportunity to access exciting new therapies to treat cancer. At AstraZeneca, I can do this by interacting with investigators across the world and have the privilege of working with an exceptional 团队 of colleagues. Together, our drive and ambition allow me to make a difference on a scale much greater than that I could hope to achieve in academia.

At AstraZeneca there is a passion to drive forward through the science but with a patient-centric focus. This is important when planning a clinical trial and also when a study is recruiting, achieved by forging great relationships with investigators to ensure proactive and collaborative dialogue.

The training at AstraZeneca gives clinicians an unparalleled technical understanding of drug-development processes that is rarely available in clinical academia. AstraZeneca offers an environment in which physicians who are intelligent, inquisitive and with a passion to learn can thrive. As an integral part of my professional role, I am able to maintain my clinical practice through one clinical session per week as part of my professional charitable activities. 


At AstraZeneca I have the privilege of working with an exceptional 团队 whose drive and ambition allow me to make a difference on a much greater scale.


The training at AstraZeneca gives clinicians a technical understanding of drug-development decisions and processes that is rarely available in clinical academia.


金沙官网

金沙app软件

金沙app软件

金沙注册

金沙app软件

金沙app软件

金沙官网金沙注册金沙平台

金沙app软件

金沙app软件

金沙登录平台入口

LATEST PROJECT

奥门金沙官网

奥门金沙官网

奥门金沙官网

奥门金沙官网


Featured publications奥门金沙官网

Phase I dose-finding and pharmacokinetic study or eribulin-liposomal formulation in patients with solid tumours金沙app软件

Evans TR, Dean E, Molife R, Lopez J, Ranson M, El-Khouly F, Ishtiaq Zubain I, Savulsky C, Reydeman L, Jia Y, Sweeting L, Greystoke A, Barriuso J, Kristeleit R.

Published Online, British Journal of Cancer, 25JAN19

First-in-human Phase 1/2 Study of Tisotumab Vedotin in Advanced and/or Metastatic Solid Tumours.金沙app软件

De Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels J-P, Arkenau H-T, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sorensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U.

Accepted in The Lancet Oncology 2018 In Press

Pharmacokinetic Effects and Safety of Olaparib in Combination with Endocrine Therapy (Tamoxifen, Anastrazole or Letrozole): A Phase I Study in Patients with Advanced Solid Tumours金沙app软件

Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer, J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E. 

Accepted in Advances in Therapy 2018 In Press

Novel Early Phase Clinical Trial Design in Oncology金沙app软件

O.Brien C, Carter L, Cook N, Dean E.

Pharmaceutical Medicine October 2017, Volume 31, Issue 5, pp297-307 

AKT inhibition in solid tumours with AKT1 mutation金沙app软件

Hyman DM, Smyth L, Donoghue M, Westin S, Bedard P, Dean E, Bando , El-Khoueiry A, Pérez-Fidalgo J, Mita A, Schellens J, Chang M, Reichel J, Bouvier N, Selcuklu S, Soumerai T, Torrisi J, Erinerji J, Ambrose H, Barrett C, Dougherty B, Foxley A, Lindemann J, McEwen R, Pass M, Shiavon G, Berger M, Chandarlapaty S, Solit D, Banerji U, Baselga J, Taylor B.

JCO In Press, Accepted Mar2017

A Phase I pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumours.金沙app软件

Soria J, Gan H, Blagden S, Plummer R, Arkenau H, Ranson Malcolm R, Evans T, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean EJ, Brwon J, Gibson D, Peddareddiagari V, Murray S, Nebot N, Mazumdar, J, Swartz L, Auger K, Fleming R, Singh R, Millward M.

Annals of Oncology. Published Online 11 October 2016.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.金沙app软件

Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TRJ, Anthoney A, Ranson M, Boddy AV, Plummer R.

European Journal of Cancer Vol 68, Nov2016, Pgs 1-10.

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.金沙app软件

First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014. 金沙app软件

*Dean E, *Basu B, , Puglisi M, Greystroke A, Ong M, Burke WM, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson MR, Banerji U. 

Clin Cancer Res. 2015 Mar 24. pii: clincanres.2422.2014. *Equal contribution

A Phase I, Dose-Escalation Study of the Multi-Targeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. 金沙app软件